TheAnaplastic Lymphoma Kinase(ALK) was originally identified in Anaplastic Large-Cell non-Hodgkin's Lymphoma (ALCL) cell lines as the product of achromosomal translocationt(2;5; p23;q35) involving theNucleophosmin(NPM1) partner[8,9]. The humanALKlocus is located at the 2p23.2–p23.1chromosome...
HMGB1 expression was analysed in 18 non-Hodgkin lymphomas and two lymphoma cell lines. 11/18 primary lymphomas expressed HMGB1 mRNA at a level exceeding the average of normal lymph nodes. Immunohistochemistry showed that HMGB1 positivity is confined to the lymphoma cells. No correlation between HMGB1...
Lymphoma, any of a group of malignant diseases of the lymphatic system, usually starting in the lymph nodes or in lymphoid tissues of other organs, such as the lungs, spleen, and skin. Lymphomas are generally classified into two types, Hodgkin disease an
Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects the skin. Here authors show that CDK9 degradation of retinoic acid receptor α is a vulnerability for CTCL and develop a degrader targeting CDK9 that synergizes with all-trans retinoic acid to reduce CTCL ...
CURE’s non-Hodgkin lymphoma (NHL) page is an extensive resource of cancer information featuring the latest NHL news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on non-Hodgkin lymphoma....
Apoptosis mediated by the CD95 (Fas/Apo-1) molecule plays a crucial role in the regulation of the B-cell immune response. In this study, we examined the function of the CD95 antigen in B-cell–derived non-Hodgkin’s lymphoma (NHL), a malignant disease of mature B cells. Membrane CD...
Late Effects of CAR T-Cell Therapy in Lymphoma Kimberly Rath, PharmD In this new analysis, investigators review the late adverse events associated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. ...
Non-Hodgkin lymphoma is further classified into a variety of subtypes based on the cell of origin (B-cell or T-cell), and the cell characteristics. The subtype of Non-Hodgkin lymphoma predicts the necessity of early treatment, the response to treatment, the type of treatment required, and th...
AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is the second most frequent cancer associated with AIDS, and is a frequent cause of death in HIV-infected individuals. Experimental analysis of AIDS-NHL has been facilitated by the availability of an excelle
Non-Hodgkin lymphoma (NHL) is not a single disease entity, but rather a group of diseases, most of which are B cell in origin, though rare types of NHL are of T or natural killer cell origin. Several immunotherapeutic agents are available for the treatment of B-cell NHL, including the ...